An efficacy study of GSK Biologicalsâ?? candidate influenza vaccine GSK2321138A in childre

Phase 3

Completed

• Registration Number: CTRI/2014/03/004497
• Lead Sponsor: GlaxoSmithKline Biologicals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 8200

Inclusion Criteria

•Subjects who the investigator believes that their parents/Legally Acceptable Representative (LARs) can and will comply with the requirements of the protocol.

•A male or female between, and including, 6 and 35 months of age at the time of first vaccination; children are eligible regardless of history of influenza vaccination.

• Written informed consent obtained from the parent(s) /LAR(s) of the subject.

•Subjects in stable health as determined by medical history and clinical examination before entering into the study.

Exclusion Criteria

•Child in care

•Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.

•Prior receipt of any influenza vaccine within 6 months preceding the first dose of study vaccine, or planned use of such vaccines during the study period.

•Children with underlying illness who are at risk of complications of influenza and for whom yearly (seasonal) influenza vaccination is recommended in their respective country.

•Any confirmed or suspected immunosuppressive or immunodeficient condition (including HIV), based on medical history and physical examination.

•Chronic administration of immunosuppressants or other immune modifying drugs within six months prior to the first vaccine dose. Inhaled and topical steroids are allowed.

•Administration of immunoglobulins and/ or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period

•Any known or suspected allergy to any constituent of influenza vaccines, non-influenza vaccine comparators and latex; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous vaccination

•Any contraindication to intramuscular injection

•Acute disease and/or fever at the time of enrolment.

•Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study

•Additional criteria for children >= 12 months of age:

-Prior receipt of any licensed varicella vaccine or any licensed hepatitis A vaccine or planned use of these vaccines during the study period. Other routine registered childhood vaccinations are permitted.

NOTE: For countries with varicella vaccine administered as 2-dose schedule, prior receipt of a single dose of a varicella vaccine is allowed if administered at least 2 weeks before the first study vaccination.

-Any history of hepatitis A or varicella diseases.

•Additional criteria for children 6 - 11 months of age in countries without universal mass vaccination recommendation for pneumococcal vaccine:

-Prior receipt of any pneumococcal conjugated vaccine or planned use of this vaccine during the study period. Other routine registered childhood vaccinations are permitted

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
First occurrence of RT-PCR confirmed influenza A and/or B disease due to any influenza strainTimepoint: During the surveillance period (approximately 6 to 8 months)